Consistently, IFNγ-driven STAT1 activation led to a 30% reduction in the bioenergetic capacity of breast cancer cells compared to the 25-fold reduction observed with phenformin treatment, either alone or combined with IFNγ (Fig. 3h and Supplementary Figure 3c). The gene discussed is STAT1; the disease is breast carcinoma.